评估医学对策高级研发与监管审批机会的框架:BARDA新发传染病战略组成部分
该文基于既往医学对策(MCM)开发经验、FDA指南及专家意见,构建了一个概念框架,用于评估针对已知病原体的疫苗和治疗药物生成关键数据以支持FDA监管审批的可行性。框架识别了八个核心因素,并应用于七种优先病原体以展示其如何指导投资决策。结论认为在现有监管范式下,疫苗开发比治疗药物更可行,但与FDA密切协商至关重要。
要点
- 框架含八个核心因素,用于评估MCM高级研发与FDA审批可行性。
- 应用框架评估七种新发病原体,辅助跨疾病背景的投资决策。
- 现有条件下疫苗开发比治疗药物更可行,监管路径因产品和背景而异。
核心结论
- 该框架通过识别最有可能在现有监管范式内获得FDA批准的MCM候选,支持更高效的资源分配。
- 在评估的病原体中,疫苗开发似乎比治疗药物更可行,但监管路径仍因产品和背景而异。
- 与FDA密切协商对于定义适当的监管策略至关重要。
研究设计与样本
- 概念框架构建,基于既往MCM开发项目经验、当前FDA指南及科学、监管和公共卫生领域专家的见解。
- 识别影响生成关键数据能力的关键要求,并根据当前流行病学、技术能力和基础设施评估满足这些要求的可能性。
- 将框架应用于一部分优先病原体以展示其效用。
主要发现
- 识别了八个对评估疫苗和治疗药物高级开发及FDA审批可行性至关重要的因素。
- 使用这些因素评估了七种新发病原体,以说明框架如何为不同疾病背景下的投资决策提供信息。
临床怎么用
- 框架可指导针对新发病毒病原体开发MCM的关键组合决策。
- 利用框架识别高潜力MCM候选,优化资源分配。
- 在定义监管策略时与FDA密切协商。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The advanced research, development, and regulatory approval of medical countermeasures (MCMs) for emerging pathogens remains critical to national health security. We created a conceptual framework to assess the feasibility of generating pivotal data to support FDA regulatory approval of vaccines and therapeutics against known pathogens. Our framework is intended to guide key portfolio decisions on developing MCMs for emerging viral pathogens. METHODS: This framework draws on prior experience with MCM development programs, current FDA guidance, and insights from scientific, regulatory, and public health subject matter experts. We identified key requirements that impact the ability to generate pivotal data and assessed the likelihood of meeting these requirements based on current epidemiology, technical capabilities, and infrastructure. To demonstrate utility, we applied the framework to a subset of prioritized pathogens. RESULTS: We identified eight factors central to assessing the feasibility of advanced development and FDA approval of vaccines and therapeutics. These factors were used to evaluate seven emerging pathogens to illustrate how the framework may inform investment decisions across disease contexts. CONCLUSIONS: This framework supports more efficient resource allocation by highlighting MCM candidates with the highest potential for FDA approval within existing regulatory paradigms. Given current conditions, vaccine development appears more feasible than therapeutics for the pathogens assessed, although regulatory pathways remain product- and context-specific. Close consultation with the FDA will be critical in defining appropriate regulatory strategies. This framework offers a structured, proactive approach to advance MCM development and strengthen national preparedness against emerging pathogens.
引用
- White RC, Lewis RG, Little JD, et al. A Framework for Assessing the Opportunity for Advanced Research, Development, and Regulatory Approval of Medical Countermeasures: A Component of BARDA's Emerging Infectious Diseases Strategy. J Infect Dis. 2026. PMID: 41063660. doi:10.1093/infdis/jiaf486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。